Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.550 EUR
−191.15 M EUR
754.78 M EUR
104.19 M
About Apellis Pharmaceuticals, Inc.
Sector
Industry
CEO
Cedric Francois
Website
Headquarters
Waltham
Founded
2009
ISIN
US03753U1060
FIGI
BBG01TNWBDG1
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
APLS5052553
Apellis Pharmaceuticals, Inc. 3.5% 15-SEP-2026Yield to maturity
—
Maturity date
Sep 15, 2026
See all 1APLS bonds
Frequently Asked Questions
The current price of 1APLS is 22.400 EUR — it has decreased by −4.98% in the past 24 hours. Watch Apellis Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange Apellis Pharmaceuticals, Inc. stocks are traded under the ticker 1APLS.
1APLS stock has fallen by −4.96% compared to the previous week, the month change is a 12.30% rise, over the last year Apellis Pharmaceuticals, Inc. has showed a 45.36% increase.
We've gathered analysts' opinions on Apellis Pharmaceuticals, Inc. future price: according to them, 1APLS price has a max estimate of 51.53 EUR and a min estimate of 16.32 EUR. Watch 1APLS chart and read a more detailed Apellis Pharmaceuticals, Inc. stock forecast: see what analysts think of Apellis Pharmaceuticals, Inc. and suggest that you do with its stocks.
1APLS reached its all-time high on Aug 27, 2025 with the price of 24.235 EUR, and its all-time low was 14.600 EUR and was reached on May 15, 2025. View more price dynamics on 1APLS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1APLS stock is 5.25% volatile and has beta coefficient of 0.87. Track Apellis Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Apellis Pharmaceuticals, Inc. there?
Today Apellis Pharmaceuticals, Inc. has the market capitalization of 2.97 B, it has decreased by −0.37% over the last week.
Yes, you can track Apellis Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Apellis Pharmaceuticals, Inc. is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
1APLS earnings for the last quarter are −0.28 EUR per share, whereas the estimation was −0.40 EUR resulting in a 29.11% surprise. The estimated earnings for the next quarter are 1.36 EUR per share. See more details about Apellis Pharmaceuticals, Inc. earnings.
Apellis Pharmaceuticals, Inc. revenue for the last quarter amounts to 145.49 M EUR, despite the estimated figure of 157.44 M EUR. In the next quarter, revenue is expected to reach 332.07 M EUR.
1APLS net income for the last quarter is −35.78 M EUR, while the quarter before that showed −85.25 M EUR of net income which accounts for 58.03% change. Track more Apellis Pharmaceuticals, Inc. financial stats to get the full picture.
No, 1APLS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 2, 2025, the company has 710 employees. See our rating of the largest employees — is Apellis Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Apellis Pharmaceuticals, Inc. EBITDA is −159.82 M EUR, and current EBITDA margin is −20.88%. See more stats in Apellis Pharmaceuticals, Inc. financial statements.
Like other stocks, 1APLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Apellis Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.